Anti-inflammatory drug cromolyn successfully delayed disease onset and was neuroprotective in a mouse model of ALS
Brings more than 20 years of experience in the life science industry to support pre-commercial and regulatory activities of Phase 3 candidate ALZT-OP1 for early Alzheimer’s disease
Monday, November 11, 2019 at 4:00 pm
Cutting-edge CAR-Treg technology could have broad application across common and rare neurodegenerative diseases; Smith Founder and CEO Philip Ashton-Rickardt, Ph.D. joins as SVP of Immunology
Proceeds to support ongoing Phase 3 Alzheimer’s clinical trial, expected to complete in 2020, and advancement of pipeline of candidates targeting neuroinflammation
Dr. Rudy Tanzi discusses AZTherapies’ approach with NBC News medical correspondent Dr. John Torres.
Investor, former biopharmaceutical executive, and philanthropist George Behrakis has joined the company’s Board of Directors.
AZTherapies, Inc. has completed target enrollment in its COGNITE Phase 3 clinical trial, evaluating the safety and efficacy of ALZT-OP1 for the treatment of early Alzheimer’s disease.
AZTherapies Strengthens Management Team, Adding Industry Veteran Jay Mohr as Chief Operating and Business Officer, Head of Commercial Development.
Presentation to highlight Company’s late-stage clinical program and unique approach to neuroinflammation and the treatment of early Alzheimer’s disease.